Zacks Investment ResearchWed, 13 May 2026 14:05:32 GMTImplied Volatility Surging for Novartis Stock OptionsNVS-0.81%
CNBCWed, 29 Apr 2026 09:32:51 GMTUK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policiesNVS-0.81%
Seeking AlphaTue, 28 Apr 2026 20:31:41 GMTNovartis AG (NVS) Q1 2026 Earnings Call TranscriptNVS-0.81%
CNBC TelevisionTue, 28 Apr 2026 17:04:31 GMTNovartis CEO warns of reality of Trump's drug pricing policyNVS-0.81%
Zacks Investment ResearchTue, 28 Apr 2026 16:16:08 GMTNovartis Q1 Earnings & Revenues Miss Estimates, Stock DownNVS-0.81%
Zacks Investment ResearchTue, 28 Apr 2026 14:31:05 GMTNovartis (NVS) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesNVS-0.81%
Investors Business DailyTue, 28 Apr 2026 13:02:51 GMTNovartis Dips As Generics Take A Bite Out Of Its First-Quarter SalesNVS-0.81%
InvezzTue, 28 Apr 2026 08:58:46 GMTNovartis shares fall after weak Q1 hit by Entresto competitionNVS-0.81%
CNBC International TVTue, 28 Apr 2026 07:54:24 GMTNovartis CEO: We knew these first two quarters would be bumpyNVS-0.81%
CNBCTue, 28 Apr 2026 07:23:34 GMTNovartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'NVS-0.81%
CNBCTue, 28 Apr 2026 05:18:33 GMTEuropean markets to open higher as Trump considers Iran peace proposalNVS-0.81%
Zacks Investment ResearchMon, 27 Apr 2026 17:20:56 GMTNVS SMA Drug Gets CHMP Backing, Malaria Drug Wins WHO PrequalificationNVS-0.81%
Zacks Investment ResearchThu, 23 Apr 2026 14:16:20 GMTUnveiling Novartis (NVS) Q1 Outlook: Wall Street Estimates for Key MetricsNVS-0.81%
Seeking AlphaTue, 21 Apr 2026 16:23:18 GMTNovartis: Buy Thesis Fades Into Q1 2026 Results (Rating Downgrade)NVS-0.81%
The Motley FoolFri, 17 Apr 2026 18:37:00 GMTBetter Pharma Dividend Stock: Novartis vs. MerckNVS-0.81%
Investors Business DailyTue, 14 Apr 2026 16:52:36 GMTBig Pharma Deepens AI Ties. What It Means For Novo, Novartis.NVS-0.81%
Zacks Investment ResearchFri, 27 Mar 2026 19:55:38 GMTNovartis Bolsters Immunology Pipeline With Excellergy DealNVS-0.81%
CNBCFri, 27 Mar 2026 11:43:54 GMTNovartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a weekNVS-0.81%
